Alzheimer's disease (AD) is a progressive neurodegenerative disorder whose cause is unknown and for which an effective therapy dose not exist. The present application proposes 5 years the funding of the University of Florida Drug Discovery Group for Alzheimer's Disease (UF-DDG) to continue the process of hypothesis-driven research into the mechanism(s), models and discovery of efficacious therapies that affect the underlying neuropathologies of AD. Four research projects and 4 supportive cores will continue the discovery of drug in 4 different therapeutic classes with efficacy in protecting neuron in vivo and in vitro and in enhancing memory- related behaviors in learning/memory deficient animal models. For a drug to emerge from our preclinical assessment and enter animal toxicity assessments, it must show neuroprotective and memory-enhancing activity. During the first funding period, this process has resulted in 3 drugs in 2 therapeutic classes entering clinical trial for efficacy assessment in AD. The present program of research proposes the assessment of the mechanism of action of the neuroprotective and cognitive-enhancing effects of our compounds, and the synthesis of novel compounds that are indicated from our studies. In Project 1, James W. Simpkins we will assess the neuroprotective activities of the estratrienes, a group of estrogen-like compounds that we have shown to be neuroprotective in a variety of in vitro and in vivo models and cognitive-enhancing in animals. Project 2, Edwin Meyer will determine the neuroprotective mechanism of novel alpha7 nicotinic agonists and we will synthesis new agonist, based upon discovered structure-activity relationships. In Project 3, Jeffrey Hughes/Edwin Meyer will continue their work on non-viral methods for the delivery of a nerve growth factor gene into brain neurons, using novels cationic liposomes that incorporate pH sensitive surfactants, designed to increase the transfection rate of the gene. The 4 cores are i) Administration, ii) Tissues Culture, iii) Animal Care and Behavioral Assessment, and iv) Neurochemistry. Collectively, these core will provide organization, reagents and services that are vital to the success of the program. In summary, this program of research will continue to discover novel drugs (and drug mechanisms) that are of potential efficacy in the treatment of the neurodegeneration and cognitive decline associated with AD.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG010485-08
Application #
2748508
Study Section
Special Emphasis Panel (ZAG1-PCR-5 (90))
Project Start
1991-09-30
Project End
1999-07-31
Budget Start
1998-08-01
Budget End
1999-07-31
Support Year
8
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Florida
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
073130411
City
Gainesville
State
FL
Country
United States
Zip Code
32611
Richter, Frank; Koulen, Peter; Kaja, Simon (2016) N-Palmitoylethanolamine Prevents the Run-down of Amplitudes in Cortical Spreading Depression Possibly Implicating Proinflammatory Cytokine Release. Sci Rep 6:23481
Means, John C; Gerdes, Bryan C; Kaja, Simon et al. (2016) Caspase-3-Dependent Proteolytic Cleavage of Tau Causes Neurofibrillary Tangles and Results in Cognitive Impairment During Normal Aging. Neurochem Res 41:2278-88
Montgomery, Christa L; Keereetaweep, Jantana; Johnson, Heather M et al. (2016) Changes in Retinal N-Acylethanolamines and their Oxylipin Derivatives During the Development of Visual Impairment in a Mouse Model for Glaucoma. Lipids 51:857-66
Kaja, Simon; Payne, Andrew J; Singh, Tulsi et al. (2015) An optimized lactate dehydrogenase release assay for screening of drug candidates in neuroscience. J Pharmacol Toxicol Methods 73:1-6
Sarkar, Saumyendra; Jun, Sujung; Simpkins, James W (2015) Estrogen amelioration of A?-induced defects in mitochondria is mediated by mitochondrial signaling pathway involving ER?, AKAP and Drp1. Brain Res 1616:101-11
Kaja, Simon; Payne, Andrew J; Naumchuk, Yuliya et al. (2015) Plate reader-based cell viability assays for glioprotection using primary rat optic nerve head astrocytes. Exp Eye Res 138:159-66
Cheli, V T; Santiago González, D A; Spreuer, V et al. (2015) Voltage-gated Ca2+ entry promotes oligodendrocyte progenitor cell maturation and myelination in vitro. Exp Neurol 265:69-83
Kaja, Simon; Sumien, Nathalie; Shah, Vidhi V et al. (2015) Loss of Spatial Memory, Learning, and Motor Function During Normal Aging Is Accompanied by Changes in Brain Presenilin 1 and 2 Expression Levels. Mol Neurobiol 52:545-54
Kaja, S; Payne, A J; Nielsen, E Ø et al. (2015) Differential cerebellar GABAA receptor expression in mice with mutations in CaV2.1 (P/Q-type) calcium channels. Neuroscience 304:198-208
Grillo, Stephanie L; Koulen, Peter (2015) Psychophysical testing in rodent models of glaucomatous optic neuropathy. Exp Eye Res 141:154-63

Showing the most recent 10 out of 233 publications